3 Fabulous Dividend Stocks to Buy in February
AbbVie projects they'll generate sales of over $31 billion ... postmenopausal osteoporosis treatment Evenity; and Tepezza, ...
Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline
LCA-0321 is a LYTAC degrader designed to specifically bind and rapidly deplete anti-TSHR autoantibodies, the underlying cause of Graves’ disease and its extrathyroidal manifestations, including ...
pharmaphorum2d
A history of Abbott and AbbVie
Instead, it allowed for a blood sample to be inoculated with a radioactive form of thyroid hormone ... The creation of AbbVie In 2011, Abbott announced it was to separate into two leading ...
MedPage Today11d
Lithium for Bipolar Disorder Linked to Higher Risk of Thyroid, Kidney Dysfunction
the potential lithium-related risk of thyroid and renal dysfunction should ... Co-authors reported relationships with AbbVie, Angelini, Lundbeck, Otsuka, Boehringer Ingelheim, Janssen, Takeda ...
pharmaphorum5d
AbbVie forges $3.9 billion oncology alliance with Genmab
AbbVie will pay Danish antibody specialist Genmab ... for Tepezza (teprotumumab), an antibody for the treatment of thyroid eye disease. Its biggest success to date by a long margin is the alliance ...
Genmab A/S: Genmab Publishes 2024 Annual Report
Company Announcement COPENHAGEN, Denmark; February 12, 2025 - Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024 ...